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Recent studies have provided important insights into the pathogenesis of inflammatory bowel disease (IBD).
The development of new therapeutic agents has been triggered by basic research and studies in mouse
models of IBD. It is expected that improved translational researchwill lead to optimized therapy and new indi-
vidualized treatment options.Introduction
Inflammatory bowel disease (IBD; Crohn’s
disease and ulcerative colitis) are defined
as chronic inflammations of the human
gastrointestinal tract not resulting from
specific pathogens. Whereas inflamma-
tion in ulcerative colitis involves the
mucosa and submucosa of the large intes-
tine, Crohn’s disease is characterized by
transmural inflammation that most fre-
quently involves the ileum and colon. It is
now widely accepted that a genetic
predisposition contributes to the develop-
ment of IBD in many patients (Strober,
2009, in this issue of Immunity; Zhang
et al., 2008; Fellermann et al., 2006). In
fact, genome-wide linkage studies identi-
fied various chromosomal regions, and
fine-mapping of these regions led to the
identification of a number of genes,
including NOD2 (CARD15) and SLC22A4
and SLC22A5 (OCTN1 and OCTN2). In
addition, genetic association studies
have identified additional IBD-suscepti-
bility genes (genes encoding IL23R, beta
defensin 2, STAT3, IRGM, PTGER4, and
ATG16L1). Importantly, many of these
genes are known to control intestinal bar-
rier function, bacterial invasion, autoph-
agy, or activation of the mucosal immune
system. Although polymorphisms or dif-
ferences in copy numbers of these genes
have been demonstrated to modulate
susceptibility to IBD (Abraham and Cho,
2009), they currently can not be used to
predict disease outcome or responsive-
ness to anti-inflammatory therapy in IBD.
This is most likely due to the complex inter-
play between numerous bacterial antigens
and various cells of the mucosal immune
system as well as the existence of
disease-modifying factors.The interaction between the commen-
sal microflora and the mucosal immune
system is modulated by antimicrobial
proteins. In this context, innate antimicro-
bial proteins such as defensins are likely
to be critical immediately after new micro-
bial challenges, whereas the specificity of
IgA response is probably of key impor-
tance for maintaining long-term homeo-
stasis with an established microbiota
(Duerkop et al., 2009, in this issue of
Immunity). Thus, it is likely that genetic
predispositions and defects in antimicro-
bial protein expression and export may
increase the likelihood of bacterial inva-
sion of the epithelial barrier with subse-
quent inflammation (Zhang et al., 2008;
Fellermann et al., 2006). Therefore, modu-
lation of the bacterial flora via recombi-
nant defensins, probiotics, or genetically
modified bacteria producing anti-inflam-
matory proteins (e.g., IL-10) have been
recently considered for therapy of IBD in
the clinic (Figure 1; Steidler et al., 2003).
Mucosal Dendritic Cells and
Macrophages as Key Players in IBD
In this issue, Warren Strober highlights
recent developments in the interaction
between the microflora and the mucosal
immune system. He points out that the
microbial flora of the intestine is a key
factor for shaping activation and function
of antigen-presenting cells such as
dendritic cells (DCs) (Strober, 2009). The
number of intestinal DCs as well as
macrophages appears to be increased in
IBD patients as compared to controls
and these cell types display signs of cell
activation and cytokine production. They
are therefore thought to play a key role
in IBD pathogenesis and T cell activation.Immunity 31, SFor instance, a macrophage subset ex-
pressing both macrophage (CD14, CD33,
CD68) and DC markers (CD205, CD209)
has been recently shown to produce large
amounts of proinflammatory cytokines,
such as IL-23, TNF-a, and IL-6, in patients
with Crohn’s disease. These CD14+ mac-
rophages contribute to IFN-g production
rather than IL-17 production by lamina
propria T cells dependent on IL-23 and
TNF-a (Kamada et al., 2008). In addition,
three subtypes of DCs, namely myeloid
DC, plasmacytoid DC, and mature DC,
have been identified in Crohn’s disease
patients. When stimulated with bac-
terial products or antigens, myeloid DCs
from Crohn’s disease produced a higher
amount of IL-23 and lower amount of
IL-10 thereby favoring Th1 cell immune
response in Crohn’s disease compared
to those from ulcerative colitis and normal
controls (Sakuraba et al., 2009). Thus,
both DCs and macrophages are likely to
contribute to the pathogenesis of chronic
intestinal inflammation in patients with
Crohn’s disease by controlling mucosal
T cell responses.
Relevance of Effector
and Regulatory T Cells in IBD
Mucosal CD4+ T lymphocytes are a
special subgroup of cells that is hypores-
ponsive to T cell receptor stimulation com-
pared to peripheral T cells and requires
costimulation to prevent programmed
cell death (apoptosis). In the healthy intes-
tine, two subtypes of CD4+ T lym-
phocytes, denoted regulatory and effec-
tor T cells, are present that are important
in maintaining mucosal homeostasis, as
illustrated by Barnes and Powrie (2009)
in this issue of Immunity. Whereas potenteptember 18, 2009 ª2009 Elsevier Inc. 357
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Figure 1. Pathogenesis of IBD and Potential Targets for Therapy
IBD appears to be caused by an unbalanced activation of the mucosal immune system via the commensal
microflora in a genetically susceptible host. Current concepts for modulation of the bacterial flora include
antimicrobial peptides such as defensins, live microorganisms such as probiotics, and genetically modi-
fied bacteria producing IL-10. In addition, the classic immunosuppressive and anti-inflammatory drugs
such as 5-aminosalicylates (5-ASA) and azathioprine are challenged by novel immunomodulatory thera-
pies including recombinant anti-inflammatory cytokines; neutralizing chimeric, humanized, or human anti-
bodies; antisense DNA; kinase inhibitors; or small molecules.regulatory T cells are important for pre-
venting uncontrolled mucosal inflamma-
tion, normal effector T cell activity is
essential for responsiveness to potentially
harmful antigens. This crucial balance
thus requires production of both pro-
and anti-inflammatory cytokines in the
normal intestine (Maynard and Weaver,
2009, in this issue of Immunity).
In IBD patients, T cells are more resis-
tant against T cell apoptosis, leading to
a marked expansion of the number of T
lymphocytes in the inflamed intestine
(Atreya et al., 2000). However, there
appears to be an expansion of both
effector and regulatory T cell subsets at
the same time. Furthermore, in contrast
to many mouse models of IBD, regulatory
T cells in IBD appear to be fully capable of
suppressing effector T cell proliferation
(Maul et al., 2005). Thus, it appears that
counterregulation is active in IBD patients
but fails sooner or later because of an
aggressive overwhelming effector T cell
response. The effector T cells display
signs of T cell activation (e.g., activation
of nuclear factor of activated T cells
[NFATc2]) that appears to be driven by
luminal antigens and antigen-presenting
cells. Because of the heightened effector
T cell activity in IBD, developmental and
functional pathways that give rise to these
cells are potential targets for therapeutic
intervention, as reviewed in this issue by358 Immunity 31, September 18, 2009 ª200Maynard and Weaver (2009). Therefore,
various studies have attempted to illumi-
nate T cell differentiation and effector
T cell activation in IBD patients (Zenewicz
et al., 2009).
Effector T cells in Crohn’s disease
produce a Th1 cell-type cytokine profile
with elevated amounts of IFN-g and these
cells express augmented amounts of the
Th1 cell-associated transcription factor
T-bet. The functional relevance of this
observation is highlighted by the finding
that T-bet deficiency in T cells prevents
colitis in various animal models of Crohn’s
disease (Neurath et al., 2002). In contrast,
the cytokine profile of lamina propria T
lymphocytes in ulcerative colitis is char-
acterized by the increased production of
the Th2 cell-type cytokines IL-5 and IL-13
and the latter cytokine has been impli-
cated in the generation of barrier dysfunc-
tion and ulcer formation in this disease
(Heller et al., 2005). In addition, tumor
necrosis factor (TNF) as disease-perpetu-
ating effector cytokine is produced by
both Th1 and Th2 cells as well as by
macrophages in IBD. The above findings
suggested that CD4+ Th1 or Th2 cells
play a functional role in IBD (Figure 2).
This concept is supported by the clinical
effects of anti-TNF antibodies in patients
with Crohn’s disease. In fact, antibodies
to TNF that are successfully used in treat-
ing Crohn’s disease patients have been9 Elsevier Inc.shown to induce rapid mucosal T cell
apoptosis, suggesting that the thera-
peutic efficacy of these antibodies is due
to the induction of T cell death (Van den
Brande et al., 2007).
The Role of IL-12 and IL-23 in IBD
Pathogenesis
Many studies have addressed the role of
IL-12 family members in IBD, because
these cytokines are known to control
T cell differentiation and activation. This
family of cytokines comprises several het-
erodimeric proteins with pleiotropic activ-
ities including IL-12 (p35 + p40), IL-23
(p19 + p40), IL-27 (EBI3 [Epstein Barr
virus-induced gene 3] + p28), and IL-35
(p35 + EBI3). IL-12 is produced by
antigen-presenting cells such as DCs or
macrophages in the human intestine. It
has been shown to play a major role in
the induction of Th1 cell differentiation
and this function is mediated via the tran-
scription factor STAT4 (Zenewicz et al.,
2009). The production of the IL-12 hetero-
dimer is induced by antigen-presenting
cells to a higher degree in Crohn’s disease
as compared to control patients and
patients with ulcerative colitis. This obser-
vation thus may at least partially account
for the differences in Th1 cell differentia-
tion between Crohn’s disease and ulcera-
tive colitis. The functional relevance of
IL-12 was highlighted by studies with
neutralizing antibodies against the p40
subunit in various murine models of
Crohn’s disease in which blockade of
p40 resulted in apoptosis of activated T
lymphocytes and marked amelioration of
chronic intestinal inflammation. There-
fore, IL-12 blockade had been suggested
as a therapeutic approach for IBD. How-
ever, it is not known whether the effects
of anti-p40 in vivo can be entirely attrib-
uted to IL-12, because the cytokine IL-
23 (p19 + p40) also contains the p40
subunit that is blocked by anti-p40 (May-
nard and Weaver, 2009; Abraham and
Cho, 2009). Indeed, with genetically engi-
neered mice and neutralizing p19 anti-
bodies it was found that IL-23 but not
IL-12 is required for the effector phase of
colonic inflammation in murine models of
T cell-dependent colitis (e.g., adoptive
transfer colitis) (Yen et al., 2006). In addi-
tion to its effects on T cells, IL-23 has
been shown to activate intestinal macro-
phages. Targeting of IL-23 is therefore of
interest in various forms of colitis.
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Figure 2. Cytokines and T Cell Subsets in the Pathogenesis of IBD: Implications for Therapy
The T cell fate below the mucosal surface in IBD is determined by a complex interplay between bacterial
antigens and innate immune mechanisms. Intestinal epithelial cells (IECs) and DCs modulate the activation
of the mucosal immune system by producing various cytokines and regulatory proteins (Strober, 2009).
Based on these, signal effector T cells may differentiate into Th1, Th2, or Th17 effector T cells that are char-
acterized by specific signature cytokines and transcription factors. Current evidence suggests that
Crohn’s disease is associated with an augmented Th1 and Th17 cell cytokine response, whereas ulcera-
tive colitis is characterized by the production of some Th2 and Th17 cell cytokines. The effector T cell
response in IBD is augmented by disease-perpetuating cytokines such as IL-6 and TNF that induce
T cell activation and prevent T cell apoptosis. The aggressive T effector cell activation is not sufficiently
counteracted by regulatory and anti-inflammatory T cells (Treg, Tr1, Th3 cells), thereby leading to mucosal
inflammation and tissue destruction.eptember 18, 2009 ª2009 Elsevier Inc. 359However, in the TNBS colitis model, IL-23
can cross-regulate IL-12 production
during initiation of T cell-dependent colitis
and prevents Th1 cell development. Thus,
IL-23 appears to control both innate
and adaptive immune responses in the
mucosal immune system via effects on
both T cells and antigen-presenting cells.
Based on the presence of IL23R muta-
tions in many IBD patients (Abraham and
Cho, 2009), it appears possible that such
mutations could be used to predict
responsiveness to anti-IL-23 p19 or anti-
IL-12 plus anti-IL-23 p40 antibody therapy
in the future. This approach might be clin-
ically relevant, because anti-IL-12 plus
anti-IL-23 p40 showed clinical efficacy in
two pilot trials in active Crohn’s disease
(Sandborn et al., 2008). However, the
question of whether blockade of IL-23
alone is effective for therapy of Crohn’s
disease needs to be addressed in future
studies. Furthermore, studies with anti-
p40 should be conducted in ulcerative
colitis.A Role for Th17 Cells in IBD?
Because IL-23 appears to play an impor-
tant role in the pathogenesis of IBD,
many recent studies have addressed the
role of the recently described Th17 cell
subset in mucosal inflammation (Kobaya-
shi et al., 2008; Maynard and Weaver,
2009). Although this T cell subset
develops independently from IL-23 via
TGF-b plus IL-6 or TGF-b plus IL-21,
Th17 cells require IL-23 for stabilization
of their phenotype and effector function.
Thus, IL-23-driven Th17 cells might play
an important role in chronic IBD (Maynard
and Weaver, 2009). Studies addressing
the role of Th17 cells in general discov-
ered that IL-17 production was higher in
control lamina propria CD4+ T cells than
in peripheral blood T cells (Kobayashi
et al., 2008). This suggests that the gut
contains large amounts of Th17 cells
and Th17 cell-promoting cytokines such
as IL-23 even under normal circum-
stances (Becker et al., 2003), and this
Th17 cell-rich milieu is apparently favored
Immunity 31, Sby the commensal microflora (Ivanov
et al., 2008). In IBD, Th17 cell-associated
cytokines, surface molecules, and tran-
scription factors (IL-6, IL-17, IL23R, IRF4,
STAT3, and RORA) were upregulated in
CD4+ T cells isolated from patients with
both ulcerative colitis and Crohn’s dis-
ease as compared to controls (Kobayashi
et al., 2008; Atreya et al., 2000; Maynard
and Weaver, 2009). These findings
suggest that Th17 cell-like cells exist in
patients with active IBD. Consistently, an
increased production of Th17 cell-associ-
ated cytokines such as IL-17A, IL-17F,
IL-22, and IL-21 was observed in IBD
patients. The latter cytokine together
with TGF-b drives the differentiation of
Th17 cells instead of the differentiation
of adaptive regulatory T cells that are
induced by TGF-b stimulation alone. In
the absence of IL-21, mucosal Th17 cell
differentiation was substantially sup-
pressed, leading to reduced severity of
murine experimental colitis (Fina et al.,
2008). Thus, IL-21-driven Th17 cell differ-
entiation appears to contribute to the
development of colitis.
Gut-resident and circulating Th17 cells
have been recently shown to express the
C-type lectin-like receptor CD161, which
is known to promote T cell expansion
(Kleinschek et al., 2009). In Crohn’s dis-
ease, mucosal CD161+ cells were shown
to have an activated Th17 cell phenotype
and produced IL-17 and interferon-g
upon stimulation with IL-23. In contrast,
in healthy subjects priming by additional
stimuli such as IL-1b was required to
enable IL-23-induced cytokine release.
The number of CD161+ Th17 cells was
increased in the mucosa of patients with
Crohn’s disease and these cells induced
expression of inflammatory mediators by
intestinal cells (Kleinschek et al., 2009).
The above findings are consistent with
the idea that Th17 cells play a regulatory
role in IBD pathogenesis and promote
tissue destruction. The clinical relevance
of this concept is underlined by the
finding that the Th17 cell-associated tran-
scription factor RORg has been shown to
control T cell-dependent colitis via effects
on the functionally redundant cytokines
IL-17A and IL-17F (Leppkes et al., 2009).
Thus, targeting of Th17 cells or Th17
cell-associated cytokines appears as
a promising approach for therapy of
patients with IBD. However, several
issues need to be addressed in future
Immunity
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redundancy between IL-17-related cyto-
kines, the plasticity of the Th17 cell
lineage in IBD, and the interaction of
Th17 cells with Th1 cells. In particular, it
should be clarified whether optimal
suppression of chronic inflammation in
IBD requires blockade of Th17 cells, Th1
cells, or both.
Clinical Implications of Research
in IBD
Many standard treatment options have
limited efficacy for treatment of active
IBD and prevention of relapse, so numer-
ous efforts have been made to identify
more potent anti-inflammatory drugs.
Subsequently, several anti-inflammatory
and immunosuppressive agents such as
5-aminosalicylates and azathioprine have
been successfully introduced for therapy
of IBD. These drugs appear to modulate
the activity of the mucosal immune sys-
tem in a specific manner. Specifically,
aminosalicylates such as mesalamine
and sulfasalazine block the nuclear factor
NF-kB signaling and induce peroxisome
proliferator-activated receptor-gamma
expression and function in intestinal
epithelial cells (Rousseaux et al., 2005).
In contrast, azathioprine appears to
exert its immunosuppressive functions
by blocking the CD28-Vav1-dependent
activity of the small GTPase Rac1 in
mucosal CD4+ T lymphocytes and thus
modulates T cell costimulation (Tiede
et al., 2003). More recent developments
in the field of immunosuppressive drugs
were encouraged or even initiated by
preclinical studies in mouse models of
IBD as well as by ex vivo studies with
patient material (Maynard and Weaver,
2009; Zenewicz et al., 2009). For instance,
the success of TNF antibodies for therapy
of IBD patients was predicted by studies
with TNF-deficient mice or neutralizing
anti-TNF in colitis models. Furthermore,
the development of anti-p40 strategies
for IBD was initiated by studies showing
increased production of p40 in the in-
flamed gut in Crohn’s disease and the
successful treatment of chronic active
experimental colitis with p40-neutralizing
antibodies. In fact, in two pilot studies,
the p40 antibodies ABT874 and ustekinu-
mab (CNTO1275) showed beneficial
effects in patients with active Crohn’s
disease via neutralization of IL-12 and
IL-23 (Sandborn et al., 2008). Recent360 Immunity 31, September 18, 2009 ª200studies suggest that IL-23-driven Th17
cells might be more relevant for IBD-
related inflammation than IL-12-driven
Th1 cells, so several companies are
currently developing p19 or IL-17 anti-
bodies to block the former rather than
the latter pathway.
In contrast to the development of p40
inhibitors, many other strategies that
were developed based on basic research
studies failed to show efficacy in con-
trolled clinical trials. Most notably, this
holds true for recombinant anti-inflam-
matory cytokines such as recombinant
IL-10 and IL-11 that were suggested as
inducers of potent anti-inflammatory or
regulatory mucosal T cell responses.
Although the reasons for these disap-
pointing results are still largely unknown,
it is possible that inducing regulatory or
anti-inflammatory T cells is less effective
in IBD as compared to targeting effector
T cells because regulatory T cell activity
appears to be augmented in these dis-
eases already (Maul et al., 2005). Alterna-
tively, the dosage and application mode
of the above cytokines might have been
suboptimal. In spite of these problems,
however, the basic research findings
have provided some unique insights into
the pathogenesis of IBD and will unequiv-
ocally help to identify potential new tar-
gets for therapy in the future (Figures 1
and 2).
One key phenomenon in clinical ther-
apy for IBD consists of the fact that only
subgroups of patients will respond to indi-
vidual anti-inflammatory agents (e.g.,
anti-TNF, p40, or azathioprine therapy)
(Sandborn et al., 2008). This observation
suggests that many different roads may
lead to macroscopic inflammation of the
mucosa in IBD and that subgroups of
patients have different effector mecha-
nisms that initiate and perpetuate mu-
cosal inflammation. Thus, more research
needs to be done to identify effector cell
populations and mechanisms in individual
patients and to predict responsiveness to
different immunosuppressive therapies. It
is likely that such research will lead to
optimized therapy and new individualized
treatment options for IBD patients in the
future.
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